August 2015 - Evolution Biotechnologies
0
archive,date,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

14 Aug

Posted at 22:23h in News by
0 Likes

Evolution Biotechnologies founder Dr. David Harper interviewed for the financial website SeekingAlpha Dr. David Harper, the founder of Evolution Biotechnologies(www.evolutionbiotech.com), has been interviewed for the US financial website SeekingAlpha (seekingalpha.com). The interview covered both Dr. Harper’s previous work on bacteriophage therapy and the new technologies being developed by Evolution Biotechnologies. The SeekingAlpha website states: "Today I had the privilege of interviewing Dr. David Harper, who just recently departed as Chief Science Officer of AmpliPhi Biosciences (OTCQB:APHB). Founder of the infectious disease pioneer Biocontrol, which conducted the first human clinical trial of a bacteriophage, Dr. Harper is a member of the Alternatives to...

10 Aug

Posted at 22:21h in News by
0 Likes

Evolution Biotechnologies announces filing of its first patent application relating to the development of biological controls for the house dust mite Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company established to expand the use of biological control into medically important areas, today announced the filing of UK patent application GB1513981.9, “Acaricides”, relating to its planned development of biological controls for the house dust mite. The application includes exemplification from the successful feasibility study previously carried out under the direction of Evolution’s Chief Officer, Dr. David Harper. “This is an important step forward for the company, with claims detailing our initial targets and including important...